about
Targeted anti-vascular therapies for ovarian cancer: current evidenceHigh dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.A phase 3 trial of bevacizumab in ovarian cancer.Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefitPaclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantationA phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.Development of antiangiogenic agents for ovarian cancer.30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational studyThe calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy.Mucinous tumours of the ovary.Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.Mucinous epithelial ovarian carcinoma.Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.Routine chest radiography following imaging-guided placement of tunneled central lines: a waste of time, money, and radiation.Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer.Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis.Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.Chemotherapy for ovarian cancer--a consensus statement on standard practice.Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.Implications of ejection fraction value for trastuzumab.A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis.Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.Discordance between the results and conclusions of ICON7 - Authors' reply.
P50
Q26830287-5F89129F-06BD-48EB-87F3-530404247745Q33441967-1261ED60-6910-44D7-BB9D-B3209BE236B4Q34030022-1131A09C-E468-4ED2-B28A-8C67D437A795Q34520190-55BB9CC2-76AA-4179-B02F-F7BB8B0681C2Q35976329-9158C1E0-0EF6-4638-9C6B-CF78A51A4B26Q35976847-35C6027A-E61E-4B25-8F04-9BFD4A8E90F8Q35977532-D52A4BE1-664E-48B4-8F73-54F822D165FCQ35981837-CFBA80E1-277A-4D18-91E3-F1BF4CE7368CQ36081574-43D75B1E-38C3-4C9C-927F-1FA4606237C6Q36116333-2052ad73-4f55-0177-7c73-3c3caf3a3a89Q36467322-7897E74D-6F9B-42B5-B1D1-C2FC5C323EDCQ36626071-7D74AF5C-9D1C-4BE4-9066-BA4A478B53A3Q36646508-944BFF05-52B1-4209-8B07-B480EAF53606Q36694190-44740F23-E61B-4818-9443-2D1C0BB32D05Q37038884-71E1043A-7E6B-430E-B75A-E5FA7784E4B8Q37263598-F29BBF7B-32F4-43E1-A12C-D0A8B685CF9AQ37565327-6C30B9E0-E86F-4861-A679-1C5A7756BEE2Q37947395-CC51DCBF-3436-4C5C-AAA7-69259AE390D7Q38040628-EC4CE7F3-007B-453A-AA4B-36340F0B59FAQ38824322-05E5B594-4B98-4E3F-B199-7C99AB00B0D0Q39612416-28260459-2A41-48A7-87F6-D106E6A11870Q39732496-3BB92C31-8E44-4B88-BFC7-B4223A7D3EFBQ41721778-BEA708C3-93D5-42D3-B0EF-DC76CF2BF0ACQ41993363-246AF393-169C-4340-A811-064CC58F6496Q42609314-830A905C-F6C0-4BF1-8366-168F734D82F3Q42626922-69DF138F-AA63-4603-A151-FD9FC0DBE71EQ42703745-F028C3A9-F201-4873-922E-3650A121D9CDQ43013521-D4193973-D93D-4791-89E0-2E8726E50F9FQ43186641-188FB501-FBA9-4989-AD3A-7DB67ADF3CC4Q43194227-BB3BD2C9-D271-4E1D-A1F6-B6363053ADEFQ43255416-F9E627DE-3179-44DB-9A0A-73CC7A422E17Q44865258-B18D46D3-3CE9-457C-B020-55D66A8A6857Q46004672-8D8D66C3-BCA3-4D3C-BD29-D3F5CCAA4EF6Q46083075-90107CAE-79A9-4EED-B6EC-66A4758D6BFCQ46463193-5B7ADDFC-6F6D-4C45-8378-A870D4305CAFQ47764566-7F9DD745-5963-4835-A8EE-D2BCF744EE39Q50944619-EB34FFFD-6D9C-4B1B-9727-62FDD0E6B248Q52815898-8739C716-C0E4-441A-91A3-808416C07B2BQ52816857-0DBE0297-96CE-40E7-8BA7-E18D7F1BF298Q52821667-BDCC9FB9-37E4-45EF-B034-7572ACD54F26
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Timothy Perren
@ast
Timothy Perren
@en
Timothy Perren
@es
Timothy Perren
@nl
Timothy Perren
@sl
type
label
Timothy Perren
@ast
Timothy Perren
@en
Timothy Perren
@es
Timothy Perren
@nl
Timothy Perren
@sl
altLabel
Perren TJ
@en
prefLabel
Timothy Perren
@ast
Timothy Perren
@en
Timothy Perren
@es
Timothy Perren
@nl
Timothy Perren
@sl
P1053
D-5387-2013
P106
P1960
IW4tWfMAAAAJ
P21
P31
P3829
P496
0000-0001-8472-8856